Phase II trial for RPA class V and VI glioblastoma: Hypofractionated radiotherapy vs temozolomide

Lire cet article en français

Takeaway

  • Hypofractionated radiation therapy provides better progression free survival (PFS) and quality-adjusted survival (QaS) compared to exclusive temozolomide chemotherapy (CHT) without causing significant differences in overall survival (OS).

Why this matters

  • There is a scarcity of studies evaluating quality of life in very poor prognostic classes (RPA V and VI) of glioblastoma patients; these findings support that while both treatments are well tolerated, hypofractionated radiotherapy may lead to better PFS and QaS compared to CHT without a significant difference in OS.

Vous souhaitez en lire plus ?

Vous souhaitez en lire plus ?

Connectez-vous à votre compte ou inscrivez-vous à Neurodiem pour consulter la suite.

Vous avez déjà un compte ? S'identifier

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.